Mitsumasa Kishimoto

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 154 publications

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 12, 2026

Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project.

Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project.

Journal: Annals of the rheumatic diseases

Published: March 30, 2026

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST.

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST.

Journal: Rheumatology (Oxford, England)

Published: February 09, 2026

Efficacy and safety of canakinumab in patients with adult-onset Still's disease: Results from an open-label phase III study in Japan.

Efficacy and safety of canakinumab in patients with adult-onset Still's disease: Results from an open-label phase III study in Japan.

Journal: Modern rheumatology

Published: November 27, 2025

Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study.

Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study.

Journal: The Lancet. Rheumatology

Published: November 12, 2025

Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.

Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.

Journal: Nature reviews. Rheumatology

Published: November 07, 2025

A case report of spontaneous remission and relapse in minimal change disease: a heterogeneous disease entity.

A case report of spontaneous remission and relapse in minimal change disease: a heterogeneous disease entity.

Journal: CEN case reports

Published: October 27, 2025

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.

Journal: Annals of the rheumatic diseases

Published: October 27, 2025

Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years.

Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years.

Journal: Arthritis research & therapy

Published: September 25, 2025

Novel Therapy.

Novel Therapy.

Journal: Best practice & research. Clinical rheumatology

Published: September 22, 2025

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.

Journal: Arthritis research & therapy

Published: August 18, 2025

Letter to the Editor Regarding "Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases".

Letter to the Editor Regarding "Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases".

Journal: Rheumatology and therapy

Published: July 29, 2025

Showing 1-12 of 154

Last Updated: 09/26/2026